ABSTRACT In this paper, we report the data from whole-genome shotgun sequencing of an Acinetobacter ursingii isolate from healthy human skin of the forearm. The bacterial genome includes 3,473 genes and carries beta-lactamase resistance genes as well as resistance genes for several heavy metals.
translocating P-type ATPase), tellurium (terZ), arsenic (arsB, arsH, arsR, arsC, and acr3), cobalt-zinc-cadmium complex (cusA, cusB, czcA, czsB, czcD, czrR, and TR), and chromium compounds (chrA).
In the bacterium genome, beta-lactamase resistance genes class A (TEM-116) and class C (BL and BLc) were found, as well as the following genes involved in drug resistance machinery: multidrug resistance efflux/transporter genes (Bcr/CflA family, RND, OML, cmeB, cmeC, MATE family of MDR efflux pumps, macA, macB, tolC, and arcB), toxic anion resistance protein, glyoxalase/bleomycin resistance/extradiol dioxygenase family protein, organic hydroperoxide resistance protein, methyl viologen resistance protein smvA, hdeD family acid-resistance protein, chemical-damaging agent resistance protein C, resistance-to-fluoroquinols genes (gyrA, and gyrB), and bile hydrolysis genes (bsh, and AKGTO).
Furthermore, we found a cluster of genes associated with colicin V and bacteriocin production (dedA, dedE, R1, R3, R4, R5, and purF) and other virulence-associated genes and genes associated with invasion and intercellular resistance, including active virulence operons involved in protein synthesis (rv0682, rv0683, rv0684, rv0685, rv1641 , rv1642, and rv1643), DNA transcription (rv0667 and rv0668), quinolinate biosynthesis (rv1594, rv1595, and rv1596), and internalin-like proteins.
Accession number(s).
This whole-genome shotgun project has been deposited in GenBank under the accession no. PTPV00000000. The version described in this paper is version PTPV01000000 and consists of sequences PTPV01000001 to PTPV01000194. The sequence of the 16S rRNA gene has been deposited in GenBank under the accession no. MH113156.
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